Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)

Raltegravir is the preferred INSTI for for treatment of antiretroviral-naïve pregnant women in the US Perinatal Guidelines, alongside Dolutegravir, and for late pregnancy. There are relatively limited information available on its use during early pregnancy, particularly the peri-conception period. The aim of the study is to assess "real-world" maternal, fetal and newborn outcomes following RAL use during pregnancy through pooled analysis of individual patient data from observational studies participating in the European Pregnancy and Paediatric Infections Cohort Collaboration.

Start Date20 Feb 2023

Sponsor / Collaborator-

NCT03954327

/ CompletedPhase 2IIT

Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)

Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, open label study will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.

Start Date01 Mar 2021

Sponsor / Collaborator

University of Alberta

[+1]

NCT04258475

/ Unknown statusPhase 4IIT

The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.

The purpose of this study is to measure change in raltegravir serum pharmacokinetics in steady state, when co-administered with calcium carbonate formulated as antacid.

Start Date09 Dec 2020

Sponsor / Collaborator

Ottawa Hospital Research Institute

100 Clinical Results associated with Raltegravir Potassium

100 Translational Medicine associated with Raltegravir Potassium

100 Patents (Medical) associated with Raltegravir Potassium

3,022

Literatures (Medical) associated with Raltegravir Potassium

01 Oct 2026·VIROLOGY

Generation and evaluation of an EcoHIV mouse model to study HIV-1 integration and expression

Article

Author: Ren, Siyao ; Liu, Jiarui ; Yang, Zihao ; Ma, Yige ; Wei, Wanrong ; Ma, Yan ; Liu, Yue ; Zhou, Ying ; Gu, Chaojiang ; Xia, Xuejiao ; Wang, Changjun ; Gao, Yang ; Li, Jiezhen ; Yu, Lei

Antiretroviral therapy suppresses HIV replication but does not purge the latent reservoirs, which remains a major barrier to cure. There is an urgent need to establish a reservoir in a mouse model for investigation of viral replication and clearance. We established an EcoHIV infection model in conventional mice by replacing HIV-1 gp120 protein with an ecotropic murine leukemia virus envelope to enable entry via the murine mCAT-1 receptor. EcoHIV can infect immunocompetent mice and multiple mutant mouse strains and replicate in CD4⁺ T cells, macrophages, and immune cells in the brain. We created and systematically validated a nested qPCR for quantitation of HIV-1/EcoHIV integration events, and we found that viral genomic integration was significantly suppressed by HIV-1 integrase inhibitors such as Raltegravir. The immunofluorescence staining indicated EcoHIV can be efficiently transmitted from infected CD4 + T cells to macrophages in vitro and EcoHIV expression was effectively inhibited by Abacavir and Raltegravir. Importantly, BLI data demonstrate that EcoHIV establishes latent reservoirs -like state in mice which can be reactivated by LRA treatment. Altogether, our model provides a valuable platform for the controlled study of HIV entry, integration, transmission, latency within tissue-resident compartments under ART and for the preclinical evaluation of latency-reversing and curative strategies.

01 Aug 2026·BIOMEDICINE & PHARMACOTHERAPY

Raloxifene and tamoxifen reshape the immunometabolic phenotype of TLRs-activated macrophages through AEBS inhibition and lysosomal stress

Article

Author: Della Torre, Sara ; Sfogliarini, Chiara ; Rizzo, Angela Maria ; Vegeto, Elisabetta ; Allegretti, Marcello ; Bernardinelli, Camilla ; Tran, Lien Hong ; Locati, Massimo ; Cesta, Maria Candida ; Corsetto, Paola Antonia ; Cattani, Franca

Macrophages are key effectors of innate immune responses and infection control, relying on Toll-like receptors (TLRs) to sense pathogens and adopt immunometabolic anti-infective phenotypes. Raloxifene (RAL) and tamoxifen (TAM) are selective estrogen receptor modulators (SERMs) known to reprogram macrophage inflammatory responses via estrogen receptor-independent mechanisms, including NRF2 activation. Although drug repurposing approaches have highlighted anti-infective properties of these compounds, supporting host-directed mechanisms, the upstream targets and immune consequences of RAL and TAM in macrophages remain undefined. Here, we investigated the biological relevance and molecular determinants of SERM-mediated immune activity in TLR-activated macrophages. Our results show that RAL and TAM modulate inflammatory cytokine expression induced by TLR7/8, TLR4, and TLR2 stimulation. Specifically, these SERMs enhance IL 1β maturation, despite reducing proIl1b mRNA levels, and increase TNF α production, while restraining IL 6 expression. Notably, IL 6 repression is more pronounced with RAL and correlates with sustained NRF2 pathway engagement, suggesting a drug-specific immunoregulatory profile. Furthermore, RAL and TAM influence cytokine regulation through cholesterol-pathway remodeling consistent with AEBS inhibition, which was associated with PI3K-NRF2 activation and NRF2-related immunometabolic adaptation. In parallel, RAL and TAM promote lysosomal perturbations, leading to the regulation of proIl1b and Tnfa mRNA levels and to cathepsin B-associated caspase-1 activation and IL1β production. Cathepsin B inhibition further enhances NRF2-target gene responses, suggesting functional crosstalk between lysosomal and NRF2-associated pathways. Overall, these findings indicate that RAL and TAM elicit an integrated immunometabolic reshaping of macrophage inflammatory phenotypes, through cholesterol-pathway remodeling and lysosomal stress, supporting SERMs as host-directed chemotherapeutic agents.

01 Aug 2026·TROPICAL MEDICINE & INTERNATIONAL HEALTH

Repositioning Antibiotics Against Plasmodium falciparum RAD5 and WD11 as Novel Antimalarial Targets

Article

Author: Albaqami, Abdullah S. ; Adam, Khalid Mohamed ; Oyewole, Oluwafemi Adebayo

ABSTRACT:

Background:

The emergence of artemisinin resistance in Plasmodium falciparum threatens the sustainability of malaria control programs and underscores the need for new therapeutic strategies. Recently, two proteins, RAD5 (PfRAD5) and WD40‐repeat protein 11 (PfWD11), have been implicated in parasite survival and drug resistance. Their druggability, however, remains underexplored.

Methods:

We integrated computational and experimental approaches to assess PfRAD5 and PfWD11 as antimalarial targets. Structural models were retrieved from AlphaFold and aligned with orthologues across Plasmodium species. A library of 216 antibiotics was screened by molecular docking, and molecular dynamics simulations. Top‐ranked compounds were tested against P. falciparum 3D7 cultures in vitro, alone and in combination, and gene expression changes in PfRAD5 and PfWD11 were quantified by qPCR. Docking identified strong binders to PfRAD5 (talampicillin, dicloxacillin, raltegravir) and PfWD11 (cervinomycin A2 monoacetate, eAmSPC 2593, puromycin).

Results:

Molecular dynamics confirmed the stability of protein–ligand complexes. In vitro, puromycin exhibited the highest inhibition (85% at 100 μg/mL), while combinations enhanced activity. The triple combination (puromycin + raltegravir + dicloxacillin) achieved complete inhibition, and puromycin + chloroquine exhibited synergistic effects at in a concentration‐dependent manner. qPCR showed consistent downregulation of PfRAD5 and PfWD11 following puromycin‐based treatments, whereas chloroquine alone upregulated PfRAD5 expression. PfRAD5 and PfWD11 represent novel antimalarial targets.

Conclusion:

Repurposed antibiotics, particularly puromycin in synergistic regimens, offer a cost‐effective strategy to counteract emerging resistance and accelerate therapeutic development.

News (Medical) associated with Raltegravir Potassium

03 Sep 2026

·www.prnewswire.com

Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program

FDA feedback supports the proposed patient population, single arm open label trial design, primary safety assessments and exploratory efficacy measures Written regulatory feedback provides guidance as Matricelf advances preparations toward a future IND submission for NewRal NESS ZIONA, Israel, Sept. 3, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing a personalized, autologous neural tissue transplant for the treatment of spinal cord injury, today announced that it has received written feedback from the U.S. Food and Drug Administration, FDA, Center for Biologics Evaluation and Research, CBER, regarding the proposed design of the Company's first in human clinical trial of NewRal. NewRal is Matricelf's investigational personalized neural tissue transplant being developed for patients with traumatic spinal cord injury. The FDA feedback was provided through a Written Response Only, WRO, interaction and was based on a limited clinical trial synopsis submitted by the Company. Based on the information provided, the FDA expressed agreement with several key components of Matricelf's proposed first in human clinical trial design, including: Proposed patient population: Adult patients with chronic, complete traumatic thoracic spinal cord injury classified as AIS A. Clinical trial design: An open label, single arm trial with an initial 12 month follow up period as a reasonable design for the initial evaluation of safety and tolerability in humans. Clinical assessments: The proposed primary safety assessments, as well as exploratory efficacy measures including ISNCSCI, MAS and SCIM III. These exploratory measures are designed to evaluate, among other parameters, neurological changes, spasticity and patients' level of functional independence. The FDA noted that these measures relate to efficacy evaluation, while the proposed early-stage clinical trial is primarily focused on safety and tolerability. The FDA also requested that Matricelf address several additional matters as part of a future Investigational New Drug, IND, submission, including trial stopping rules, objective patient discharge criteria, additional details regarding the surgical procedure and imaging criteria for patient selection. Matricelf believes the written feedback provides important regulatory guidance as the Company continues preparing its planned IND package and advances NewRal toward clinical development. Gil Hakim, Chief Executive Officer of Matricelf, commented: "The FDA's feedback represents another important step in Matricelf's transition toward clinical development. The FDA's agreement with key elements of our proposed first in human trial, including the patient population, trial structure, safety assessments and the use of exploratory efficacy measures, gives us valuable regulatory guidance as we prepare for a future IND submission. We will now incorporate the FDA's comments and continue advancing NewRal toward the clinic." About NewRal NewRal is Matricelf's investigational personalized neural tissue transplant designed to repair damaged neural tissue following spinal cord injury. The Company's platform combines patient derived cellular components, including induced pluripotent stem cells, with a biomaterial scaffold derived from the patient's own tissue to create an autologous engineered neural tissue transplant. NewRal remains investigational, has not been approved by the FDA or any other regulatory authority, and has not yet been evaluated in humans. About Matricelf Matricelf Ltd. is a regenerative medicine company developing personalized, engineered tissue therapies intended to restore function following severe tissue injury. The Company's lead program, NewRal, is being developed as an autologous engineered neural tissue transplant for traumatic spinal cord injury. Matricelf's technology is based on research originating from Tel Aviv University and combines patient derived cells with an extracellular matrix scaffold derived from the patient's own tissue. Matricelf is publicly traded on the Tel Aviv Stock Exchange under the symbol MTLF. Forward Looking Statements This press release contains forward looking statements, including statements regarding the significance of the FDA feedback, completion of requested modifications and additional information, preparation and potential submission of an IND, regulatory review of any future IND, commencement and timing of clinical trials, clinical development of NewRal and the potential safety or efficacy of the Company's technology. Forward looking statements are based on current expectations and information available to Matricelf as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, the possibility that the FDA may request additional or different information following review of a complete IND submission, delays or difficulties in product development or clinical manufacturing, results of additional studies and testing, regulatory requirements and the Company's need for additional financing. The FDA feedback described in this release was based on a limited clinical trial synopsis and does not constitute review or clearance of a complete IND application or authorization to initiate a clinical trial. There can be no assurance that an IND will be submitted, that the FDA will permit the proposed clinical trial to proceed, or that any clinical trial will begin according to the Company's anticipated timeline, if at all. CONTACT INFO: Gil Hakim CEO Matricelf Tel: +972-52-5263351 [email protected] SOURCE Matricelf Ltd. 21% more press release views with Request a Demo

Clinical Study

22 Apr 2026

·www.biospace.com

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”),” today announced the completion of enrollment in its Phase 2 clinical study (ClinicalTrials.gov Identifier: NCT06699836 ) evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients with CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC), also known as CLOVER – C CR5-targeting L eronlimab With O ral Chemotherapy and V EGF-inhibitor E nriched R egimen. The open-label, randomized, two-arm, multi-center study is evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients who have progressed following prior standard therapies. With enrollment now complete, CytoDyn will advance the study through treatment and follow-up, with resulting data expected to inform the program’s development strategy and potential next steps. “Completing enrollment in this Phase 2 study marks an important milestone for CytoDyn and for the continued development of leronlimab in oncology,” said Dr. Jacob Lalezari, Chief Executive Officer of CytoDyn. “We are grateful to the patients, investigators, and clinical sites whose commitment made completion of enrollment possible and look forward to evaluating the study results.” “CLOVER is designed to prospectively assess the activity of leronlimab in combination with an established regimen in a difficult to treat and highly refractory patient population with microsatellite stable (MSS) metastatic colorectal cancer, ” said Pashtoon M. Kasi, M.D., M.S., Principal Investigator of the study and Medical Director of GI Oncology, City of Hope Orange County, Irvine, California. “With enrollment now complete, the study is well positioned to generate meaningful insights in this patient population with a high unmet need.” The CLOVER study builds on emerging clinical and translational findings from CytoDyn’s ongoing Phase 2 mCRC program, including data being presented at the AACR Annual Meeting 2026. Preliminary results demonstrated early signals of clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, including rapid reductions in circulating tumor DNA and modulation of immune-related markers. These findings support further evaluation of CCR5 inhibition as a strategy to enhance anti-tumor activity in metastatic colorectal cancer. Leronlimab is a monoclonal antibody targeting CCR5, a receptor involved in immune cell trafficking and tumor biology. By blocking CCR5, leronlimab may help modulate the tumor microenvironment and enhance the activity of existing therapies in difficult-to-treat cancers. CytoDyn plans to share topline data from the study as they become available. About the Phase 2 mCRC Study (NCT06699836) This Phase 2 clinical study is an open-label, randomized, two-arm, multi-center study evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients with CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC), also known as CLOVER – C CR5-targeting L eronlimab With O ral Chemotherapy and V EGF-inhibitor E nriched R egimen. Approximately 60 patients were enrolled and randomized 1:1 to receive either 350 mg or 700 mg of leronlimab in combination with standard-of-care therapy. Eligible participants are adults with histologically confirmed mCRC who have progressed following prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, where appropriate, anti-EGFR therapy. The primary endpoint of the study is objective response rate (ORR), as defined by RECIST v1.1 criteria. Secondary endpoints include safety and tolerability, duration of response, and overall survival. Patients will be followed for up to 12 months. About CytoDyn CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide. For more information, please visit and follow us on LinkedIn . Note Regarding Forward-Looking Statements This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law. Corporate Contact CytoDyn Inc. ir@cytodyn.com Media Contacts David Schull or Ignacio Guerrero-Ros, Ph.D. Russo Partners, LLC CytoDyn@russopartnersllc.com

Phase 2Clinical ResultAACR

10 Jun 2025

·www.biospace.com

Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision

iStock, Nuthawut Somsuk Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused five clinical trials. Gilead also stressed that the hold does not impact any other assets in its HIV pipeline. Five clinical trials for Gilead’s investigational weekly HIV combo pill have been placed on hold by the FDA after a safety signal emerged. While the combo includes a version of Gilead’s lenacapavir, which is approved as Sunleca for twice-yearly treatment of people with multi-drug-resistant HIV and currently under FDA review for the prevention of HIV, Jefferies analysts said the pause will not affect the looming decision date. Gilead announced the clinical hold Tuesday morning, explaining in a release that two Phase II/III trials named WONDERS-1 and -2 had been paused, plus three Phase I studies. The combination therapy features the integrase strand transfer inhibitor GS-1720 and/or the capsid inhibitor GS-4182. While Gilead did not mention lenacapavir in the release, Jefferies analysts explained that GS-4182 is a pro-drug formulation of the investigational therapy, which is separately under review for HIV pre-exposure prophylaxis (PrEP). “While it might increase some investor uncertainty into the all-important June 19 PDUFA for [lenacapavir] for PrEP, we see no major read-through and expect an on-time and clean FDA approval,” Jefferies wrote on Tuesday morning. BMO Capital Markets agreed but said that Gilead’s shares could still face some pressure Tuesday as investors digest the news. The company’s stock declined 2% to $110.75 as of 10:50 a.m. ET. Gilead said that the hold was placed after decreases in CD4+ T cell and absolute lymphocyte counts were identified in a subset of patients who received both drugs. This can be a signal of a weakened immune system in patients with HIV. The Phase II/III WONDERS-1 trial is comparing the combo with Gilead’s approved HIV medicine Biktarvy in people with HIV who are taking medication to suppress the virus. The Phase II/III WONDERS-2 study similarly features Biktarvy as the comparator but has enrolled patients with HIV who are treatment-naive. The company underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold. Gilead also stressed that the hold does not impact any other assets in its HIV pipeline. Jefferies agreed with this assessment, noting that had the FDA been concerned, it would have stalled more of Gilead’s formulations and integrase inhibitors currently under development. Any Day Now Gilead is seeking approval of lenacapavir as a twice-yearly injection for PrEP for HIV. The FDA’s decision, due June 19, has been eagerly anticipated by analysts, patients and Gilead, which is gearing up for a massive launch. The company is looking to the drug to build on its HIV empire, which is anchored by Biktarvy—a drug that recorded sales of $13.4 billion in 2024. BMO predicts peak sales of $6.5 billion for the PrEP indication. More broadly, Gilead is aiming to launch nine new HIV drugs by 2033. Gilead backed lenacapavir’s latest application with data from the Phase III PURPOSE 1 and PURPOSE 2 studies. PURPOSE 1, which focused on cisgender women, demonstrated 100% efficacy in preventing HIV infection. PURPOSE 2 enrolled a more diverse population of cisgender men, transgender men, transgender women and nonbinary individuals who have sex with partners assigned male at birth. Results showed that twice-yearly lenacapavir cut HIV incidence by 96% . Jefferies said this indication is very different from what the combo has been aimed at addressing in the now-stalled trials. It’s also unclear if the lenacapavir pro-drug is even the issue at this point. Other companies in the HIV space have had similar safety signals arise. Merck, for example, had trials of Isentress, launched in 2007, placed on hold by the FDA after CD4 T cell count reductions were observed. A combo of Isentress and Gilead’s lenacapavir for HIV treatment was also placed on hold several years ago but was ultimately released in 2022 using lower doses of Merck’s drug. Altogether, Jefferies is not too worried about the clinical hold. The firm places more weight on Phase I data for lenacapavir in combination with the injectable integrase inhibitors GS-1219 and GS-3242. Gilead intends to pick one of those medicines to move forward in a combo regimen with lenacapavir by the end of the year. The drugs are administered as a single dose at the first month and sixth month (Q6M). “This would be the real game changer and value proposition for Gilead if they are able to swap the $15B Biktarvy market onto long-acting Q6M injectable in the later half of the decade,” Jefferies wrote.

Phase 3Clinical ResultDrug ApprovalPhase 1Phase 2

100 Deals associated with Raltegravir Potassium

External Link

KEGG	Wiki	ATC	Drug Bank
D07133	Raltegravir Potassium	J05AX08	DB06817

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Merck Sharp & Dohme Corp.	12 Oct 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	NDA/BLA	European Union	Viatris Ltd. (New Zealand)	-
Kidney Failure, Chronic	Phase 3	France	Merck Sharp & Dohme Corp.	01 Dec 2011
Hypertriglyceridemia	Phase 3	United States	Merck Sharp & Dohme Corp.	01 May 2009
AIDS-Related Opportunistic Infections	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Canada	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	France	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Italy	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Poland	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Spain	Merck Sharp & Dohme Corp.	01 Jul 2008
HIV Seropositivity	Phase 3	-	Merck Sharp & Dohme Corp.	01 May 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2026	Phase 4	HIV Infections	60	BIC/FTC/TAF plus DRV/cob	rqkjjmkghi(iymtuxbdaw) = kmbespwfcd biyngtxwuu (qwpbbsmtrp ) View more	Non-inferior	26 Jul 2026
				DRV/r, RAL, TDF	rqkjjmkghi(iymtuxbdaw) = biglnjwozb biyngtxwuu (qwpbbsmtrp ) View more
NCT03311945 (CTgov)	Phase 3	HIV Seropositivity	33	Lamivudine+raltegravir	oravsujsgl = ifwvltvtcu mzgyprjkmy (iilenrgmdz, euioutkaqd - gxssznvxty) View more	-	18 Jul 2025
NCT03029689 (RAGTIME, CTgov)	Phase 3	HIV Infections	61	Current ART+raltegravir (Current ART + Raltegravir)	efebgxeqhm(pyidhleymo) = qlxokjwdga qhmizwerqb (nctijdjpih, qhwgnbijpg - jinfjpcega) View more	-	13 Apr 2025
				Current ART (Current ART + Placebo)	efebgxeqhm(pyidhleymo) = rqmhqkatwm qhmizwerqb (nctijdjpih, hmkarrejnc - qkwwgdccac) View more
NCT01854762 (PregnantHIV, CTgov)	Phase 2/3	Pregnancy \| HIV Infections	33	Raltegravir (Raltegravir)	wmwkmbtisn = eqxkjbyndc ttapnrnfwc (zhiufehmmz, epkcxewtwt - iaitqxxhyv) View more	-	15 Oct 2024
				Lopinavir/Ritonavir (Lopinavir/Ritonavir)	wmwkmbtisn = ogggixntxa ttapnrnfwc (zhiufehmmz, qunvsljajy - eyilpbzcdb) View more
IAS2024	Not Applicable	-	13,997	2NRTI+dolutegravir	itytwhunag(dbxfhlmkxe) = dqlrdfhavz faimuagocf (qatmpslvjd )	Negative	22 Jul 2024
				2NRTI+raltegravir	itytwhunag(dbxfhlmkxe) = nozhvttulj faimuagocf (qatmpslvjd )
ANRS 12300 Reflate TB 2 (IAS2023)	Phase 3	HIV Infections	453	Raltegravir-based ART	kdlezsjzut(fzklrqunbh) = sjusnpdzrm fdiacjtanc (hsmqftssjr )	Positive	23 Jul 2023
				Efavirenz-based ART	kdlezsjzut(fzklrqunbh) = ziqhemrbdc fdiacjtanc (hsmqftssjr )
NCT01641367 (ACTG A5288, Pubmed)	Phase 4	Third line	257	RAL	sihyojmkfc(dxozefartp) = tkxivbbbcq ejtbgqjzbd (otxpoibyxj ) View more	-	01 Jun 2022
				DRV/r	swuwjelvzy(sfgnndbuqk) = dhuniusxkn lviczwntki (biffevuyxo )
NCT03374358 (Pubmed \| AIDS Patient Care STDS)	Phase 4	-	43	Switch to Raltegravir	ercgssxoyr(luubcgqpuq) = xhfrshwyat qhcaghtifq (fuqnyyunlu ) View more	-	01 Sep 2021
				Continue unchanged antiretroviral therapy	ptkscfkfqo(bnobigxddz) = pwasrgocvp vhmyapgitn (mvyipdmlnt )
NCT01147107 (CTgov)	Phase 4	HIV Infections \| Hepatitis C, Chronic	80	raltegravir (Raltegravir Based Therapy)	nrelwcjgea = mocmbwvijm culduidvft (mpvywitylv, plvvqjigfj - fftandwvud) View more	-	13 Aug 2021
				Efavirenz (Efavirenz Based Therapy)	nrelwcjgea = ampwxyzujc culduidvft (mpvywitylv, igfssbqido - odfoegiahi) View more
NCT03374358 (OBERAL, CTgov)	Phase 4	Metabolic Syndrome \| Fatty Liver \| HIV Seropositivity	45	raltegravir	vaulhzfamq(cfroorkect) = xbedewsofe uciwghhpow (iajqhphlma, qkqmltmqup - lchcmkhdcj) View more	-	07 Jul 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis